INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

LONG-TERM OUTCOMRS AND FOLLOW-UP AFTER INTERVENTRICULER INTERVENTIONS

Enes Arslan

Yalova State Hospital, Department of Cardiology, Yalova, Türkiye

Arslan E. Long-term Outcomrs and Follow-up After Interventriculer Interventions. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.481-487.

ABSTRACT

Ventricular septal defect (VSD) closure and alcohol septum ablation (ASA) are the main interventricular procedures. Interventricular interventions performed with transcatheter methods offer a minimally invasive alternative to conventional surgery and provide advantages such as lower morbidity and faster recovery time in selected patients. While VSD closure provides successful anatomical closure in appropriate patients, post-procedural follow-up is required for complications such as residual shunt, arrhythmia, valvular pathologies and device embolization. ASA reduces morbidity and mortality in patients with obstructive hypertrophic cardiomyopathy by providing septal thinning and reduction in left ventricular outflow tract (LVOT) gradient. The need for a permanent pacemaker requires follow-up for final maximal LVOT gradient, change in functional class and residual obstruction. The long-term results published so far support the efficacy and safety of both procedures. However, appropriate patient selection and operator experience are crucial for a successful outcome.

Keywords: Interventricular interventions; Ventricular septal defect; Alcohol septum ablation; Prognosis

Referanslar

  1. Penny DJ, Vick GW 3rd. Ventricular septal defect. Lancet. 2011;377(9771):1103-1112. [Crossref]  [PubMed]
  2. Lillehei CW, Cohen M, Warden HE, Ziegler NR, Varco RL. The results of direct vision closure of ventricular septal defects in eight patients by means of controlled cross circulation. Surg Gynecol Obstet. 1955 Oct;101(4):446-66. [PubMed]
  3. Visconti KJ, Bichell DP, Jonas RA, Newburger JW, Bellinger DC. Developmental outcome after surgical versus interventional closure of secundum atrial septal defect in children. Circulation. 1999 Nov 9;100(19 Suppl):II145-50. [Crossref]  [PubMed]
  4. Monro JL, Alexiou C, Salmon AP, Keeton BR. Reoperations and survival after primary repair of congenital heart defects in children. J Thorac Cardiovasc Surg. 2003 Aug;126(2):511-20. [Crossref]  [PubMed]
  5. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, Van Domburg R, Van Rijen EH, Utens EM, Bogers AJ, Simoons ML. Outcome of patients after surgical closure of ventricular septal defect at young age: longitudinal follow-up of 22-34 years. Eur Heart J. 2004 Jun;25(12):1057-62. [Crossref]  [PubMed]
  6. Lock JE, Block PC, McKay RG, Baim DS, Keane JF. Transcatheter closure of ventricular septal defects. Circulation. 1988 Aug;78(2):361-8. [Crossref]  [PubMed]
  7. Sideris EB, Walsh KP, Haddad JL, Chen CR, Ren SG, Kulkarni H. Occlusion of congenital ventricular septal defects by the buttoned device. "Buttoned device" Clinical Trials International Register. Heart. 1997;77(3):276-279. [Crossref]  [PubMed]  [PMC]
  8. Amin Z, Gu X, Berry JM, et al. New device for closure of muscular ventricular septal defects in a canine model. Circulation. 1999;100(3):320-328. [Crossref]  [PubMed]
  9. Christodorescu R, Corrado D, D'Alto M. 2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal. 2021;42:563À645. [Link]
  10. Song J. Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects. Korean Circ J. 2023 Mar;53(3):134-150. [Crossref]  [PubMed]  [PMC]
  11. Wang L, Cao S, Li J, et al. Transcatheter closure of congenital perimembranous ventricular septal defect in children using symmetric occluders: an 8-year multiinstitutional experience. Ann Thorac Surg. 2012;94(2):592-598. Epub 2012 May 23. [Crossref]  [PubMed]
  12. Haas NA, Kock L, Bertram H, Boekenkamp R, De Wolf D, et al. Interventional VSD-Closure with the Nit-Occlud((R)) Le VSD-Coil in 110 patients: early and midterm results of the EUREVECO-Registry. Pediatr Cardiol. 2017;38(2):215-227 [Crossref]  [PubMed]
  13. Zuo J, Xie J, Yi W, Yang J, Zhang J, Li J, Yi D. Results of transcatheter closure of perimembranous ventricular septal defect. Am J Cardiol. 2010 Oct 1;106(7):1034-7. [Crossref]  [PubMed]
  14. Scully BB, Morales DL, Zafar F, McKenzie ED, Fraser CD Jr, Heinle JS. Current expectations for surgical repair of isolated ventricular septal defects. Ann Thorac Surg. 2010 Feb;89(2):544-9; discussion 550-1. [Crossref]  [PubMed]
  15. Hijazi ZM, Hakim F, Haweleh AA, et al. Catheter closure of perimembranous ventricular septal defects using the newAmplatzer membranous VSD occluder: initial clinical experience. Catheter Cardiovasc Interv. 2002;56(4):508-515. [Crossref]  [PubMed]
  16. Yip WC, Zimmerman F, Hijazi ZM. Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect. Catheter Cardiovasc Interv. 2005 Nov;66(3):436-41. [Crossref]  [PubMed]
  17. Walsh MA, Bialkowski J, Szkutnik M, Pawelec-Wojtalik M, Bobkowski W, Walsh KP. Atrioventricular block after transcatheter closure of perimembranous ventricular septal defects. Heart. 2006 Sep;92(9):1295-7. Epub 2006 Jan 31. [Crossref]  [PubMed]  [PMC]
  18. Santhanam H, Yang L, Chen Z, Tai BC, Rajgor DD, Quek SC. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol. 2018 Mar 1;254:75-83. Epub 2017 Dec 7. [Crossref]  [PubMed]
  19. Yang L, Tai BC, Khin LW, Quek SC. A systematic review on the efficacy and safety of transcatheter device closure of ventricular septal defects (VSD). J Interv Cardiol. 2014 Jun;27(3):260-72. Epub 2014 Apr 29. [Crossref]  [PubMed]
  20. Schlotter F, de Waha S, Eitel I, Desch S, Fuernau G, Thiele H. Interventional post-myocardial infarction ventricular septal defect closure: a systematic review of current evidence. EuroIntervention. 2016 May 17;12(1):94-102. [Crossref]  [PubMed]
  21. Taha FA, Alnozha F, Amoudi O, Almutairi M, Abuelatta R. Transcatheter Closure of Residual and Iatrogenic Ventricular Septal Defects: Tertiary Center Experience and Outcome. Pediatr Cardiol. 2022 Feb;43(2):308-323. Epub 2021 Sep 8. [Crossref]  [PubMed]
  22. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). European heart journal. 2024:44(39);3948-4042. [Link]
  23. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212-e260. [PubMed]
  24. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975;52:88-102. [Crossref]  [PubMed]
  25. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214. [Crossref]  [PubMed]
  26. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. [PubMed]
  27. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Aug 20;150(8):e198. [Crossref]  [PubMed]
  28. Maron BJ, Yacoub M, Dearani JA. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back to European patients. Eur Heart J. 2011;32:1055-1058. [Crossref]  [PubMed]
  29. Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-1523. Epub 2016 Jan 7. [Crossref]  [PubMed]
  30. Shloido E, Popov K, Chernyshov S, Kashtanov M. National experience of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A long-term multicenter retrospective study. Indian Heart J. 2024;76(6):390-397. [Crossref]  [PubMed]  [PMC]
  31. Fernandes V, Karimianpour A, Rier JD, Shaji S, Mullinax BJ, Wahlquist AH, Nielsen CD. Long-Term Survival After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Experience. J Invasive Cardiol. 2021 Oct;33(10):E769-E776. Epub 2021 Sep 23. [Crossref]  [PubMed]
  32. Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. 2018 Dec 18;72(24):3087-3094. [Crossref]  [PubMed]
  33. Matsuda J, Takano H, Imori Y, Ishihara K, Sangen H, Kubota Y, et al. Long-term clinical outcomes after alcohol septal ablation for hypertrophic obstructive cardiomyopathy in Japan: a retrospective study. Heart Vessels. 2024 Nov 24. Epub ahead of print. [Crossref]
  34. El-Sabawi B, Nishimura RA, Eleid MF. Response by El-Sabawi et al to Letter Regarding Article, "Temporal Occurrence of Arrhythmic Complications After Alcohol Septal Ablation". Circulation: Cardiovascular Interventions. 2020;13(3):e009059. [Crossref]  [PubMed]
  35. Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823-834. [Crossref]  [PubMed]
  36. Singh K, Qutub M, Carson K, et al. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88:107-115. [Crossref]  [PubMed]
  37. Kimmelstiel C, Zisa DC, Kuttab JS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv 2019;12:e007673. [Crossref]  [PubMed]  [PMC]
  38. Sorajja P, Ommen SR, Holmes DR Jr, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012; 126:2374. [Crossref]  [PubMed]
  39. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation 1994; 90:1781. [Crossref]  [PubMed]
  40. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033. [Crossref]  [PubMed]
  41. Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol. 2004;93:171. [Crossref]  [PubMed]
  42. Chen AA, Palacios IF, Mela T, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006;97:264. [Crossref]  [PubMed]
  43. Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49:350. [Crossref]  [PubMed]
  44. Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2015;3:896. [Crossref]  [PubMed]
  45. Balt JC, Wijffels MC, Boersma LV, et al. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy. Heart 2014; 100:1865. [Crossref]  [PubMed]
  46. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010 May;3(3):362-9. Epub 2010 Mar 23. [Crossref]  [PubMed]
  47. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. J Am Coll Cardiol. 2015 Sep 15;66(11):1307-1308. [Link]
  48. Patel N, Shetty NS, Gaonkar M, et al. Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy. J Am Heart Assoc. 2024;13(21):e036387. [Crossref]  [PubMed]  [PMC]